EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Zileuton, a 5-Lypoxigenase Inhibitor, is Antiparasitic and Prevents Inflammation in the Chronic Stage of Heart Chagas Disease

Mayra Fernanda Ricci, Estela Mariana Guimarães Lourenço, Rafaela das Dores Pereira, Ronan Ricardo Sabino Araújo, Fernando Bento Rodrigues Oliveira, Elany Barbosa da Silva iD, Gabriel Stephani de Oliveira, Mauro Martins Teixeira, Nazareth de Novaes Rocha, Felipe Santiago Chambergo, Danilo Roman-Campos, Jader Santos Cruz und 2 weitere

ACS Infectious Diseases · 2024

DOI: 10.1021/acsinfecdis.4c00623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Mayra Fernanda Ricci und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Ge…. Hauptthemen laut MEDLINE: Hydroxyurea, Trypanosoma cruzi, Chagas Cardiomyopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, National Institute for Science and Technology in Dengue and Host-microbial interactions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic Chagas cardiomyopathy is associated with an unbalanced immune response and impaired heart function, and available drugs do not prevent its development. Zileuton (Zi), a 5-lypoxigenase inhibitor, affects inflammatory/pro-resolution mediators. Herein, Zi treatment in the early phase of infection reduced parasitemia associated mainly with the direct effect of Zi on the parasite, and the enzyme epoxide hydrolase was the potential molecular target behind the trypanocidal effect. In the intermediate acute phase of infection, Zi reduced the number of innate and adaptive inflammatory cells, increased the level of SOCS2 expression in the heart associated with lower inflammation, and improved cardiac function. Zi treatment initiated in the chronic stage increased the level of SOCS2 expression in the heart, reduced inflammation, and improved cardiac function. Our data suggest that Zi protects against Trypanosoma cruzi infection by acting directly on the parasite and reducing heart damage and is a promising option for the treatment of Chagas disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxyureaTrypanosoma cruziChagas CardiomyopathyAnimalsMiceInflammationChronic DiseaseMaleAntiparasitic AgentsParasitemia

Stichwörter der Autor:innen

Chagas diseasecardiomyopathyepoxide hydrolaseimmunoregulationtrypanocidal effectzileuton

Substanzen

zileutonHydroxyureaAntiparasitic Agents

Autor:innen und Institutionen

  • Department of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Gerais, Brazil.
  • Department of Microbiology, Institute of Biomedical Sciences, Universidade de São Paulo, São Paulo 05508-000, Brazil.
  • Program in Health Sciences: Infectious Diseases and Tropical Medicine/Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Ger…
  • Department of Physiology and Pharmacology, Biomedical Institute, Universidade Federal Fluminense, Niterói 24020-141, Rio de Janeiro, Brazil.
  • School of Arts, Sciences and Humanities, Universidade de São Paulo, São Paulo 03828-000, Brazil.
  • Department of Biophysics, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil.

ORCID-Profile: Elany Barbosa da Silva, Fabiana Simão Machado

Förderung

  • Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais
  • Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
  • National Institute for Science and Technology in Dengue and Host-microbial interactions

Zitieren

APA

Ricci, M. F., Lourenço, E. M. G., Pereira, R. D. D., Araújo, R. R. S., Oliveira, F. B. R., Barbosa da Silva, E., de Oliveira, G. S., Teixeira, M. M., Rocha, N. N., Chambergo, F. S., Roman-Campos, D., Cruz, J. S., Ferreira, R. S., & Machado, F. S. (2024). Zileuton, a 5-Lypoxigenase Inhibitor, is Antiparasitic and Prevents Inflammation in the Chronic Stage of Heart Chagas Disease. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00623

Vancouver

Ricci MF, Lourenço EMG, Pereira RDD, Araújo RRS, Oliveira FBR, Barbosa da Silva E, et al. Zileuton, a 5-Lypoxigenase Inhibitor, is Antiparasitic and Prevents Inflammation in the Chronic Stage of Heart Chagas Disease. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00623

BibTeX
@article{Ricci2024,
  author = {Ricci, Mayra Fernanda and Lourenço, Estela Mariana Guimarães and Pereira, Rafaela das Dores and Araújo, Ronan Ricardo Sabino and Oliveira, Fernando Bento Rodrigues and Barbosa da Silva, Elany and de Oliveira, Gabriel Stephani and Teixeira, Mauro Martins and Rocha, Nazareth de Novaes and Chambergo, Felipe Santiago and Roman-Campos, Danilo and Cruz, Jader Santos and Ferreira, Rafaela Salgado and Machado, Fabiana Simão},
  title = {Zileuton, a 5-Lypoxigenase Inhibitor, is Antiparasitic and Prevents Inflammation in the Chronic Stage of Heart Chagas Disease},
  journal = {ACS Infectious Diseases},
  year = {2024},
  doi = {10.1021/acsinfecdis.4c00623}
}
Kostenlos starten →